Name: 글로벌 시장 동향
SKU: PH621
Availability: InStock

보고서 요약(국문)

보고서 개요
세계 우르소데옥시콜산(UDCA) 시장은 2023년 5억 8,117만 달러에 달했으며, 2024년부터 2031년까지 연평균 9.8%의 성장률로 2031년에는 11억 2,055만 달러에 이를 것으로 예상됩니다.

우르소데옥시콜산(UDCA)은 담즙정체성 간질환의 치료 및 관리에 사용되는 치료제입니다. 이는 간 및 담낭 질환 치료제의 활성 의약품 성분(API)으로서 중요한 역할을 하는 담즙산입니다. UDCA는 천연 자원에서 추출하거나 실험실에서 합성할 수 있습니다.
UDCA는 주로 간에서 생성되는 소화액인 담즙의 구성을 변화시켜 작용합니다. 담즙 내 콜레스테롤 농도를 낮춰 담즙의 콜레스테롤 포화도를 감소시킵니다. 담즙 내 콜레스테롤 수치가 높으면 담석 형성을 유발할 수 있기 때문에 이러한 작용은 중요합니다. 콜레스테롤 담석 용해를 촉진하는 UDCA는 특히 연령이나 동반 질환 등 다양한 건강 문제로 수술이 어려운 환자에게 비수술적 치료 옵션으로 활용될 수 있습니다.
시장 동향: 주요 동인
간 질환 유병률 증가
전 세계 우르소데옥시콜산(UDCA) 시장 수요는 여러 요인에 의해 주도되고 있습니다. 그중 가장 중요한 요인은 간 질환 유병률의 증가입니다. 전 세계적으로 간 질환, 특히 원발성 담즙성 담관염(PBC) 및 비알코올성 지방간 질환(NAFLD)과 같은 담즙정체성 간 질환의 부담이 크게 증가하고 있습니다. 이러한 증가는 주로 생활 습관 변화, 비만, 고령화에 기인하며, 이는 우르소데옥시콜산(UDCA)과 같은 치료제에 대한 수요 증가로 이어집니다.
2023년 2월 NCBI 연구 보고서에 따르면, 비알코올성 지방간 질환(NAFLD)은 전 세계적으로 가장 흔한 간 질환 중 하나입니다. 전 세계적으로 비알코올성 지방간 질환(NAFLD)의 발생률은 인구 1,000명당 약 47명으로 추산되며, 남성이 여성보다 발생률이 높습니다. 또한, 성인의 전 세계 NAFLD 유병률은 약 32%로 추산되며, 남성의 40%, 여성의 26%가 영향을 받습니다.
이러한 시장 성장은 업계 주요 기업들의 신제품 출시, 정부의 연구 개발 활동과 같은 정책, 그리고 증가하는 임상 시험 건수 등에 의해 견인되고 있습니다. 예를 들어, 업계 주요 기업 중 하나인 바이오필드 파마(Biofield Pharma Pvt Ltd)는 우르소데옥시콜산 300mg을 함유한 정제 형태의 'URSOGET'이라는 신제품을 출시했습니다. 이 정제는 알루미늄-알루미늄 블리스터 팩에 포장되어 있으며, 각 팩에는 10정(10 x 10 크기)이 들어 있습니다.
또한, 2023년 6월에는 입센(Ipsen)과 젠핏(GENFIT)이 핵심 3상 임상 시험인 ELATIVE에서 긍정적인 주요 결과를 발표했습니다. 임상시험에서는 희귀 담즙정체성 간질환인 원발성 담즙성 담관염(PBC) 환자 중 현재 표준 치료법인 우르소데옥시콜산(UDCA)에 대한 반응이 불충분하거나 내약성이 없는 환자를 대상으로, 연구 단계에 있는 이중 α, δ PPAR 작용제인 엘라피브라노르의 효능과 안전성을 평가하고 있습니다.
제한 요인
UDCA 관련 부작용, 대체 치료 옵션의 존재, 규제 문제, 그리고 환자들의 낮은 인식 수준 등이 시장 성장을 저해할 것으로 예상됩니다.
시장 세분화 분석
전 세계 우르소데옥시콜산 시장은 유형, 형태, 적용 분야, 유통 채널 및 지역별로 세분화됩니다.
원발성 담즙성 담관염(PBC) 부문은 전 세계 우르소데옥시콜산 시장 점유율의 약 48.6%를 차지했습니다.
원발성 담즙성 담관염(PBC) 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 원발성 담즙성 담관염(PBC)은 간 내 담관이 점진적으로 파괴되는 만성 자가면역 간 질환입니다. 이 질환에서는 면역 체계가 담관 내벽 세포를 잘못 공격하여 염증과 흉터를 유발합니다. 이러한 손상은 담관의 점진적인 협착과 폐쇄로 이어져 간에서 담즙이 정상적으로 흐르지 못하게 합니다.
손상된 담관으로 인해 간에 담즙이 축적되면 추가적인 염증을 유발하고 간 조직을 더욱 손상시킬 수 있습니다. 시간이 지남에 따라 이러한 축적은 간경변증으로 이어질 수 있는데, 이는 건강한 간 조직이 흉터 조직으로 대체되어 간 기능이 심각하게 저하되는 질환입니다.
또한, 업계 주요 업체들이 UDCA 치료에 더욱 집중하고 임상 시험에서 긍정적인 결과를 얻으면서 이 분야의 시장 성장을 견인하고 있습니다. 예를 들어, 2023년 8월 CymaBay Therapeutics, Inc.는 원발성 담즙성 담관염(PBC) 치료를 위한 셀라델파르의 효능을 평가하는 ENHANCE 3상 글로벌 연구 결과가 간학(Hepatology) 저널에 게재되었다고 발표했습니다. 이 연구는 1차 치료제, 특히 우르소데옥시콜산(UDCA)에 적절히 반응하지 않은 PBC 환자에서 선택적 퍼옥시좀 증식인자 활성화 수용체 델타(PPAR-델타) 작용제인 셀라델파르의 안전성과 효능을 조사한다는 점에서 중요합니다.
시장 지역별 점유율
북미는 전 세계 우르소데옥시콜산 시장의 약 43.4%를 차지했습니다.
북미 지역은 간 질환, 특히 원발성 담즙성 담관염(PBC), 원발성 경화성 담관염(PSC), 비알코올성 지방간 질환(NAFLD)의 유병률 증가로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상되며, 이는 북미 지역의 우르소데옥시콜산(UDCA) 수요를 견인하는 주요 요인입니다.
또한, 이 지역에는 주요 기업들이 다수 포진해 있고, 잘 발달된 의료 인프라와 활발한 연구 개발 활동이 시장 성장을 촉진하고 있습니다. 2022년 10월 NCBI 연구 보고서에 따르면, 미국에서는 약 2천만~2천5백만 명이 담석증을 앓고 있으며, 이는 심각한 건강 합병증을 유발할 수 있습니다. 담석은 담낭에 형성될 수 있는 소화액의 경화된 침전물입니다. 많은 사람들이 담석을 가지고 있지만, 모든 사람이 증상을 경험하거나 치료를 필요로 하는 것은 아닙니다. 그러나 증상이 있거나 치료가 필요한 경우, 증상 완화 및 합병증 예방을 위해 매년 70만 건 이상의 담낭절제술(담낭 제거 수술)이 시행됩니다.
또한, 주요 제약회사의 신제품 출시 및 승인이 이러한 시장 성장을 견인하고 있습니다. 예를 들어, 2024년 6월 입센(Ipsen)은 미국 식품의약국(FDA)이 원발성 담즙성 담관염(PBC) 치료제인 이키르보(Iqirvo, 엘라피브라노르)에 대해 신속 승인을 otorg했다고 발표했습니다. 이 승인을 통해 이키르보는 우르소데옥시콜산(UDCA) 치료에 충분한 반응을 보이지 않는 성인 환자에게 UDCA와 병용하여 사용할 수 있게 되었으며, UDCA를 견딜 수 없는 환자에게는 단독 요법으로 사용할 수 있게 되었습니다.

시장 세분화
유형별
합성 우르소데옥시콜산(UDCA)
생물학적 우르소데옥시콜산(UDCA)
형태별
정제
캡슐
현탁액
적용 분야별
담석
원발성 담즙성 담관염(PBC)
원발성 경화성 담관염(PSC)
비알코올성 지방간 질환(NAFLD)
기타 간 및 담도 질환
유통 채널별
병원 약국
소매 약국
온라인 약국
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
스페인
이탈리아
기타 유럽
남미
브라질
아르헨티나
기타 남미
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양
중동 및 아프리카
시장 경쟁 환경
우르소데옥시콜산 시장의 주요 글로벌 업체로는 Glenmark Pharmaceuticals Inc., Biobrick Pharma, Casca Remedies Pvt. Ltd., Wellona Pharma, ADDII BIOTECH PRIVATE LIMITED., Curivo Healthcare, Zoic Life Sciences, Biofield Pharma Pvt Ltd, Jabs Biotech Pvt. Ltd, Captee 등이 있습니다.
주요 개발 사항
2024년 8월, Gilead Sciences, Inc.는 미국 식품의약국(FDA)이 원발성 담즙성 담관염(PBC) 치료제인 Livdelzi(셀라델파르)에 대해 신속 승인을 otorg했다고 발표했습니다. 이 승인을 통해 Livdelzi는 우르소데옥시콜산(UDCA)에 적절히 반응하지 않는 성인 환자에게 UDCA와 병용하여 사용하거나, UDCA를 견딜 수 없는 환자에게 단독 요법으로 사용할 수 있게 되었습니다.
보고서 구매 이유

본 보고서는 유형, 형태, 응용 분야, 유통 채널 및 지역별 글로벌 우르소데옥시콜산 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악하는 데 도움을 줍니다.

트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.
모든 세그먼트를 포함한 우르소데옥시콜산 시장의 다양한 데이터 포인트가 담긴 엑셀 시트가 제공됩니다.
PDF 보고서는 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석 자료입니다.
주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료(엑셀 파일)도 제공됩니다.
글로벌 우르소데옥시콜산 시장 보고서는 약 70개의 표, 63개의 그림, 183페이지 분량입니다.
주요 고객 (2024년 기준)
제조업체/구매자
산업 투자자/투자은행
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global Ursodeoxycholic Acid Market reached US$ 581.17 million in 2023 and is expected to reach US$ 1120.55 million by 2031 growing with a CAGR of 9.8% during the forecast period 2024-2031.
Ursodeoxycholic acid (UDCA) is a therapeutic agent utilized in the treatment and management of cholestatic liver diseases. It is a bile acid that plays a crucial role as an active pharmaceutical ingredient (API) in medications aimed at treating liver and gallbladder disorders. It is either isolated from natural sources or synthesized in laboratories.
UDCA functions primarily by modifying the composition of bile, which is a digestive fluid produced by the liver. It reduces the concentration of cholesterol in bile, thereby decreasing the saturation of bile with cholesterol. This action is significant because high cholesterol levels in bile can lead to the formation of gallstones. By promoting the dissolution of cholesterol gallstones, UDCA serves as a non-surgical treatment option, particularly for patients who are not candidates for surgery due to various health concerns, such as age or comorbidities.
Market Dynamics: Drivers
Increasing prevalence of liver diseases
The demand for the global ursodeoxycholic acid market is driven by multiple factors. One of the primary factors is the increasing prevalence of liver diseases. The global burden of liver diseases, particularly cholestatic liver disorders such as primary biliary cholangitis (PBC) and non-alcoholic fatty liver disease (NAFLD), is increasing significantly. This rise is largely attributed to lifestyle changes, obesity, and an aging population, which collectively contribute to a higher demand for therapeutic agents like ursodeoxycholic acid (UDCA).
As per NCBI research publication in February 2023, nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases globally. The estimated global incidence of NAFLD is approximately 47 cases per 1,000 individuals, with a higher occurrence in males than in females. Furthermore, the estimated global prevalence of NAFLD among adults stands at 32%, with 40% of men affected compared to 26% of women.
Moreover, key players in the industry product launches, government initiatives such as R&D activities, and a rising number of clinical trials are driving this market growth. For instance, one of the major players in the industry Biofield Pharma Pvt Ltd has launched a new product called 'URSOGET' containing 300 mg of ursodeoxycholic acid as a tablet. The tablets are packaged in ALU-ALU blister packs, with each pack containing 10 tablets (10 x 10 size).
Also, in June 2023, Ipsen and GENFIT stated positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual α, δ PPAR agonist, is being assessed for the treatment of patients with the rare cholestatic liver disease, Primary Biliary Cholangitis, who have an inadequate response or intolerance to the current standard of care therapy, ursodeoxycholic acid.
Restraints
Factors such as adverse effects associated with the UDCA, availability of alternative treatment options, regulatory challenges, and limited awareness among individuals, are expected to hamper the market.
Market Segment Analysis
The global ursodeoxycholic acid market is segmented based on type, form, application, distribution channels, and region.
The primary biliary cholangitis (PBC) segment accounted for approximately 48.6% of the global ursodeoxycholic acid market share
The primary biliary cholangitis (PBC) segment is expected to hold the largest market share over the forecast period. Primary biliary cholangitis (PBC) is a long-lasting autoimmune liver disease marked by the gradual destruction of the bile ducts within the liver. In this condition, the immune system erroneously targets the cells that line the bile ducts, resulting in inflammation and scarring. This damage leads to the gradual narrowing and blockage of the bile ducts, which hampers the normal flow of bile from the liver.
As bile builds up in the liver due to these damaged ducts, it can trigger additional inflammation and further harm the liver tissue. Over time, this accumulation may result in cirrhosis, a serious condition where healthy liver tissue is replaced by scar tissue, severely impairing the liver's functionality.
Moreover, key players in the industry more focus on UDCA treatment, and getting positive results from the clinical trials are helping to propel this segment's growth in the market. For instance, in August 2023, CymaBay Therapeutics, Inc. announced that results from the ENHANCE phase 3 global study evaluating seladelpar for treating primary biliary cholangitis (PBC) have been published in the journal Hepatology. This study is significant as it investigates the safety and efficacy of seladelpar, a selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist, in patients with PBC who have not responded adequately to first-line treatments, particularly ursodeoxycholic acid (UDCA).
Market Geographical Share
North America accounted for approximately 43.4% of the global ursodeoxycholic acid market share
North America region is expected to hold the largest market share over the forecast period owing to the increasing prevalence of liver diseases, particularly primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and non-alcoholic fatty liver disease (NAFLD), is a significant driver for the demand for ursodeoxycholic acid (UDCA) in North America.
Moreover, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, and growing R&D activities are driving this market growth. As per NCBI research publications in October 2022, in the United States, an estimated 20-25 million people are affected by gallstones, a condition that can lead to significant health complications. Gallstones are hardened deposits of digestive fluid that can form in the gallbladder, and while many individuals may have gallstones, not all will experience symptoms or require treatment. However, for those who do, over 700,000 cholecystectomies (surgical removal of the gallbladder) are performed annually to alleviate symptoms and prevent complications.
In addition, key player's product launches and approvals are driving this market growth. For instance, in June 2024, Ipsen announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo (elafibranor) for treating primary biliary cholangitis (PBC). This approval permits the use of Iqirvo in two specific situations in conjunction with ursodeoxycholic acid (UDCA) for adults who have not shown sufficient response to UDCA treatment. As a standalone therapy for patients who are unable to tolerate UDCA.
Market Segmentation
By Type
Synthetic Ursodeoxycholic Acid (UDCA)
Biological Ursodeoxycholic Acid (UDCA)
By Form
Tablets
Capsules
Suspension
By Application
Gallstones
Primary Biliary Cholangitis (PBC)
Primary Sclerosing Cholangitis (PSC)
Non-Alcoholic Fatty Liver Disease (NAFLD)
Other Liver and Biliary Diseases
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
The rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the ursodeoxycholic acid market include Glenmark Pharmaceuticals Inc., Biobrick Pharma, Casca Remedies Pvt. Ltd., Wellona Pharma, ADDII BIOTECH PRIVATE LIMITED., Curivo Healthcare, Zoic Life Sciences, Biofield Pharma Pvt Ltd, Jabs Biotech Pvt. Ltd, and Captee among others.
Key Developments
In August 2024, Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC). This approval allows Livdelzi to be used in combination with ursodeoxycholic acid (UDCA) for adults who have not responded adequately to UDCA and as a monotherapy for patients who are unable to tolerate UDCA.
Why Purchase the Report?
To visualize the global ursodeoxycholic acid market segmentation based on type, form, application, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the ursodeoxycholic acid market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global ursodeoxycholic acid market report would provide approximately 70 tables, 63 figures, and 183 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Form
3.3. Snippet by Application
3.4. Snippet by Distribution Channels
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Liver Diseases
4.1.2. Restraints
4.1.2.1. Adverse Effects Associated with the UDCA
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Synthetic Ursodeoxycholic Acid (UDCA)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Biological Ursodeoxycholic Acid (UDCA)
7. By Form
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
7.1.2. Market Attractiveness Index, By Form
7.2. Tablets *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Capsules
7.4. Suspension
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Gallstones *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Primary Biliary Cholangitis (PBC)
8.4. Primary Sclerosing Cholangitis (PSC)
8.5. Non-Alcoholic Fatty Liver Disease (NAFLD)
8.6. Other Liver and Biliary Diseases
9. By Distribution Channels
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.1.2. Market Attractiveness Index, By Distribution Channels
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Glenmark Pharmaceuticals Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Biobrick Pharma
12.3. Casca Remedies Pvt. Ltd.
12.4. Wellona Pharma
12.5. ADDII BIOTECH PRIVATE LIMITED.
12.6. Curivo Healthcare
12.7. Zoic Life Sciences
12.8. Biofield Pharma Pvt Ltd
12.9. Jabs Biotech Pvt. Ltd
12.10. Captab (*LIST NOT EXHAUSTIVE)
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Glenmark Pharmaceuticals Inc., 4.	Key Developments, Biobrick Pharma, Casca Remedies Pvt. Ltd., Wellona Pharma, ADDII BIOTECH PRIVATE LIMITED., Curivo Healthcare, Zoic Life Sciences, Biofield Pharma Pvt Ltd, Jabs Biotech Pvt. Ltd

표 목록 (Tables)

List of Tables

Table 1 Global Ursodeoxycholic Acid Market Value, By Technology, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Ursodeoxycholic Acid Market Value, By Form, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Ursodeoxycholic Acid Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Ursodeoxycholic Acid Market Value, By Distribution Channels, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Ursodeoxycholic Acid Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Ursodeoxycholic Acid Market Value, By Technology, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Ursodeoxycholic Acid Market Value, By Technology, 2022-2031 (US$ Million)

Table 8 Global Ursodeoxycholic Acid Market Value, By Form, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Ursodeoxycholic Acid Market Value, By Form, 2022-2031 (US$ Million)

Table 10 Global Ursodeoxycholic Acid Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Ursodeoxycholic Acid Market Value, By Application, 2022-2031 (US$ Million)

Table 12 Global Ursodeoxycholic Acid Market Value, By Distribution Channels, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Ursodeoxycholic Acid Market Value, By Distribution Channels, 2022-2031 (US$ Million)

Table 14 Global Ursodeoxycholic Acid Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Ursodeoxycholic Acid Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Ursodeoxycholic Acid Market Value, By Technology, 2022-2031 (US$ Million)

Table 17 North America Ursodeoxycholic Acid Market Value, By Form, 2022-2031 (US$ Million)

Table 18 North America Ursodeoxycholic Acid Market Value, By Application, 2022-2031 (US$ Million)

Table 19 North America Ursodeoxycholic Acid Market Value, By Distribution Channels, 2022-2031 (US$ Million)

Table 20 North America Ursodeoxycholic Acid Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Asia-Pacific Ursodeoxycholic Acid Market Value, By Technology, 2022-2031 (US$ Million)

Table 22 Asia-Pacific Ursodeoxycholic Acid Market Value, By Form, 2022-2031 (US$ Million)

Table 23 Asia-Pacific Ursodeoxycholic Acid Market Value, By Application, 2022-2031 (US$ Million)

Table 24 Asia-Pacific Ursodeoxycholic Acid Market Value, By Distribution Channels, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Ursodeoxycholic Acid Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Ursodeoxycholic Acid Market Value, By Technology, 2022-2031 (US$ Million)

Table 27 Europe Ursodeoxycholic Acid Market Value, By Form, 2022-2031 (US$ Million)

Table 28 Europe Ursodeoxycholic Acid Market Value, By Application, 2022-2031 (US$ Million)

Table 29 Europe Ursodeoxycholic Acid Market Value, By Distribution Channels, 2022-2031 (US$ Million)

Table 30 Europe Ursodeoxycholic Acid Market Value, By Country, 2022-2031 (US$ Million)

Table 31 South America Ursodeoxycholic Acid Market Value, By Technology, 2022-2031 (US$ Million)

Table 32 South America Ursodeoxycholic Acid Market Value, By Form, 2022-2031 (US$ Million)

Table 33 South America Ursodeoxycholic Acid Market Value, By Application, 2022-2031 (US$ Million)

Table 34 South America Ursodeoxycholic Acid Market Value, By Distribution Channels, 2022-2031 (US$ Million)

Table 35 South America Ursodeoxycholic Acid Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East and Africa Ursodeoxycholic Acid Market Value, By Technology, 2022-2031 (US$ Million)

Table 37 Middle East and Africa Ursodeoxycholic Acid Market Value, By Form, 2022-2031 (US$ Million)

Table 38 Middle East and Africa Ursodeoxycholic Acid Market Value, By Application, 2022-2031 (US$ Million)

Table 39 Middle East and Africa Ursodeoxycholic Acid Market Value, By Distribution Channels, 2022-2031 (US$ Million)

Table 40 Middle East and Africa Ursodeoxycholic Acid Market Value, By Country, 2022-2031 (US$ Million)

Table 41 Glenmark Pharmaceuticals Inc.: Overview

Table 42 Glenmark Pharmaceuticals Inc.: Product Portfolio

Table 43 Glenmark Pharmaceuticals Inc.: Key Developments

Table 44 Biobrick Pharma: Overview

Table 45 Biobrick Pharma: Product Portfolio

Table 46 Biobrick Pharma: Key Developments

Table 47 Casca Remedies Pvt. Ltd.: Overview

Table 48 Casca Remedies Pvt. Ltd.: Product Portfolio

Table 49 Casca Remedies Pvt. Ltd.: Key Developments

Table 50 Wellona Pharma: Overview

Table 51 Wellona Pharma: Product Portfolio

Table 52 Wellona Pharma: Key Developments

Table 53 ADDII BIOTECH PRIVATE LIMITED.: Overview

Table 54 ADDII BIOTECH PRIVATE LIMITED.: Product Portfolio

Table 55 ADDII BIOTECH PRIVATE LIMITED.: Key Developments

Table 56 Curivo Healthcare: Overview

Table 57 Curivo Healthcare: Product Portfolio

Table 58 Curivo Healthcare: Key Developments

Table 59 Zoic Life Sciences: Overview

Table 60 Zoic Life Sciences: Product Portfolio

Table 61 Zoic Life Sciences: Key Developments

Table 62 Biofield Pharma Pvt Ltd: Overview

Table 63 Biofield Pharma Pvt Ltd: Product Portfolio

Table 64 Biofield Pharma Pvt Ltd: Key Developments

Table 65 Jabs Biotech Pvt. Ltd: Overview

Table 66 Jabs Biotech Pvt. Ltd: Product Portfolio

Table 67 Jabs Biotech Pvt. Ltd: Key Developments

Table 68 Captab: Overview

Table 69 Captab: Product Portfolio

그림 목록 (Figures)

List of Figures

Figure 1 Global Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 2 Global Ursodeoxycholic Acid Market Share, By Technology, 2023 & 2031 (%)

Figure 3 Global Ursodeoxycholic Acid Market Share, By Form, 2023 & 2031 (%)

Figure 4 Global Ursodeoxycholic Acid Market Share, By Application, 2023 & 2031 (%)

Figure 5 Global Ursodeoxycholic Acid Market Share, By Distribution Channels, 2023 & 2031 (%)

Figure 6 Global Ursodeoxycholic Acid Market Share, By Region, 2023 & 2031 (%)

Figure 7 Global Ursodeoxycholic Acid Market Y-o-Y Growth, By Technology, 2023-2031 (%)

Figure 8 Synthetic Ursodeoxycholic Acid (UDCA) Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 9 Biological Ursodeoxycholic Acid (UDCA) Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 10 Global Ursodeoxycholic Acid Market Y-o-Y Growth, By Form, 2023-2031 (%)

Figure 11 Tablets Form in Global Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 12 Capsules Form in Global Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 13 Suspension Form in Global Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 14 Global Ursodeoxycholic Acid Market Y-o-Y Growth, By Application, 2023-2031 (%)

Figure 15 Gallstones Application in Global Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 16 Primary Biliary Cholangitis (PBC) Application in Global Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 17 Primary Sclerosing Cholangitis (PSC) Application in Global Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 18 Non-Alcoholic Fatty Liver Disease (NAFLD) Application in Global Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 19 Other Liver and Biliary Diseases Application in Global Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 20 Global Ursodeoxycholic Acid Market Y-o-Y Growth, By Distribution Channels, 2023-2031 (%)

Figure 21 Hospital Pharmacies Distribution Channels in Global Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 22 Retail Pharmacies Distribution Channels in Global Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 23 Online Pharmacies Distribution Channels in Global Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 24 Global Ursodeoxycholic Acid Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 25 North America Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 26 North America Ursodeoxycholic Acid Market Share, By Technology, 2023 & 2031 (%)

Figure 27 North America Ursodeoxycholic Acid Market Share, By Form, 2023 & 2031 (%)

Figure 28 North America Ursodeoxycholic Acid Market Share, By Application, 2023 & 2031 (%)

Figure 29 North America Ursodeoxycholic Acid Market Share, By Distribution Channels, 2023 & 2031 (%)

Figure 30 North America Ursodeoxycholic Acid Market Share, By Country, 2023 & 2031 (%)

Figure 31 Asia-Pacific Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 32 Asia-Pacific Ursodeoxycholic Acid Market Share, By Technology, 2023 & 2031 (%)

Figure 33 Asia-Pacific Ursodeoxycholic Acid Market Share, By Form, 2023 & 2031 (%)

Figure 34 Asia-Pacific Ursodeoxycholic Acid Market Share, By Application, 2023 & 2031 (%)

Figure 35 Asia-Pacific Ursodeoxycholic Acid Market Share, By Distribution Channels, 2023 & 2031 (%)

Figure 36 Asia-Pacific Ursodeoxycholic Acid Market Share, By Country, 2023 & 2031 (%)

Figure 37 Europe Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 38 Europe Ursodeoxycholic Acid Market Share, By Technology, 2023 & 2031 (%)

Figure 39 Europe Ursodeoxycholic Acid Market Share, By Form, 2023 & 2031 (%)

Figure 40 Europe Ursodeoxycholic Acid Market Share, By Application, 2023 & 2031 (%)

Figure 41 Europe Ursodeoxycholic Acid Market Share, By Distribution Channels, 2023 & 2031 (%)

Figure 42 Europe Ursodeoxycholic Acid Market Share, By Country, 2023 & 2031 (%)

Figure 43 South America Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 44 South America Ursodeoxycholic Acid Market Share, By Technology, 2023 & 2031 (%)

Figure 45 South America Ursodeoxycholic Acid Market Share, By Form, 2023 & 2031 (%)

Figure 46 South America Ursodeoxycholic Acid Market Share, By Application, 2023 & 2031 (%)

Figure 47 South America Ursodeoxycholic Acid Market Share, By Distribution Channels, 2023 & 2031 (%)

Figure 48 South America Ursodeoxycholic Acid Market Share, By Country, 2023 & 2031 (%)

Figure 49 Middle East and Africa Ursodeoxycholic Acid Market Value, 2022-2031 (US$ Million)

Figure 50 Middle East and Africa Ursodeoxycholic Acid Market Share, By Technology, 2023 & 2031 (%)

Figure 51 Middle East and Africa Ursodeoxycholic Acid Market Share, By Form, 2023 & 2031 (%)

Figure 52 Middle East and Africa Ursodeoxycholic Acid Market Share, By Application, 2023 & 2031 (%)

Figure 53 Middle East and Africa Ursodeoxycholic Acid Market Share, By Distribution Channels, 2023 & 2031 (%)

Figure 54 Glenmark Pharmaceuticals Inc.: Financials

Figure 55 Biobrick Pharma: Financials

Figure 56 Casca Remedies Pvt. Ltd.: Financials

Figure 57 Wellona Pharma: Financials

Figure 58 ADDII BIOTECH PRIVATE LIMITED.: Financials

Figure 59 Curivo Healthcare: Financials

Figure 60 Zoic Life Sciences: Financials

Figure 61 Biofield Pharma Pvt Ltd: Financials

Figure 62 Jabs Biotech Pvt. Ltd: Financials

Figure 63 Captab: Financials

세계 우르소데옥시콜산 시장 – 2024-2031

Global Ursodeoxycholic Acid Market - 2024-2031